---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032926"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:43:29.708771+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cingulate increases ATM offering capacity by $2.86M; receives European patent for ADHD drug CTx-1301

## Summary
- Increased maximum aggregate offering of common stock under Sales Agreement from $8.47M to $11.33M; filed prospectus supplement for $2.86M in additional shares.
- Previously sold $8.47M of common stock under the Sales Agreement with H.C. Wainwright & Co.
- European patent (EP 3261625) granted for lead asset CTx-1301 (dexmethylphenidate) for ADHD on August 14, 2024.
- Patent covers up to 30 European territories, including the United Kingdom.

## SEC filing metadata
- accession: 0001493152-24-032926
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315224032926/0001493152-24-032926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315224032926/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032926
- JSON: https://secwatch.observer/filing/0001493152-24-032926.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032926.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.